

Reza Ghasemi

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/10600645/publications.pdf>

Version: 2024-02-01

9
papers

186
citations

1478505

6
h-index

1588992

8
g-index

9
all docs

9
docs citations

9
times ranked

465
citing authors

#	ARTICLE	IF	CITATIONS
1	Selective targeting of IL-2 to NKG2D bearing cells for improved immunotherapy. Nature Communications, 2016, 7, 12878.	12.8	51
2	Silibinin inhibits invasive properties of human glioblastoma U87MG cells through suppression of cathepsin B and nuclear factor kappa B-mediated induction of matrix metalloproteinase 9. Anti-Cancer Drugs, 2010, 21, 252-260.	1.4	35
3	Dacomitinib, a pan-inhibitor of ErbB receptors, suppresses growth and invasive capacity of chemoresistant ovarian carcinoma cells. Scientific Reports, 2017, 7, 4204.	3.3	27
4	Multitargeting and Antimetastatic Potentials of Silibinin in Human HepG-2 and PLC/PRF/5 Hepatoma Cells. Nutrition and Cancer, 2013, 65, 590-599.	2.0	25
5	Contribution of CTCF binding to transcriptional activity at the HOXA locus in NPM1-mutant AML cells. Leukemia, 2021, 35, 404-416.	7.2	20
6	Effects of silibinin on growth and invasive properties of human ovarian carcinoma cells through suppression of heregulin/HER3 pathway. Tumor Biology, 2016, 37, 3913-3923.	1.8	13
7	Deficiency of the adaptor protein Sly1 results in a natural killer cell ribosomopathy affecting tumor clearance. Oncoimmunology, 2016, 5, e1238543.	4.6	8
8	Targeting of IL-2 to cytotoxic lymphocytes as an improved method of cytokine-driven immunotherapy. Oncoimmunology, 2017, 6, e1265721.	4.6	7
9	Homozygous Loss of a Critical CTCF Recognition Sequence in the HOXA gene Cluster Eliminates CTCF Binding but Does Not Appreciably Reduce HOXA9 expression in NPM1 Mutated AML Cells. Blood, 2018, 132, 2613-2613.	1.4	0